Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade

This article was originally published in Scrip

Executive Summary

The drug development landscape has changed markedly over the 20 years since the EMA was founded in 1995, with a pronounced shift away from the blockbuster model to a more personalized approach involving diagnostic tools, more patient involvement, and the earlier availability of promising new drugs for unmet needs. Maureen Kenny and Ian Schofield spoke to Guido Rasi, former EMA executive director and now its principal adviser on strategy, about the complexity of the EU regulatory system, why it's OK to give companies scientific advice, and what the drug evaluation landscape might look like in the next 10-20 years.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts